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 Neurotensin is a neuropeptide neurotransmitter that interacts with multiple 
neurotransmitter systems, including those regulating amygdalar function, via NTS1 and NTS2 
receptors. Both receptors are expressed in the amygdala and agonists for NTS1 or NTS2 receptors 
have exhibited anxiolytic effects in animal models. Systemic adminstration of NTS1 receptor 
agonist PD149163 was recently shown to reduce footshock conditioned 22-kHz ultrasonic 
vocalizations in rats, suggesting that PD149163 produced an anxiolytic effect. The effects that 
neurotensin may have or a selective NTS2 receptor agonist may have on 22-kHz vocalizations 
has yet to be examined. The current study evaluated the effects of intracerebroventricularly 
administered neurotensin (0.1 - 10.0µg), PD149163 (0.1-10.0 ng), or the NTS2 receptor agonist 
JMV-431 (0.1 - 1.0 μg) on footshock conditioned 22-kHz vocalizations in male Wistar rats. 
Neurotensin, PD149163, and JMV-431 all significantly reduced the number 22-kHz calls. No 
changes in call duration were found, suggesting that non-specific drug effects do not account for 
the reductions in 22-kHz calls. These data support anxiolytic effects produced by activation of 
NTS1 or NTS2 receptors, and suggest that neurotensin plays a natural role in the expression of 
conditioned USVs. These data suggest that both receptor subtypes are putative pharmacologic 
targets.   
 









































































Neurotensin is a neuropeptide neurotransmitter distributed throughout much of the CNS 
and that interacts with a number of neurotransmitter systems through NTS1 or NTS2 receptors 
(Kleczkowska and Lipkowski, 2013; Vincent et al., 1999). Soon after its discovery by Carraway 
and Leeman (Carraway and Leeman, 1973), studies found that intracranial administration of 
neurotensin produced some physiological and behavioral effects similar to those produced by 
antipsychotic drugs (Jolicoeur et al., 1993; Nemeroff, 1980). These findings formed the basis for 
developing a number of synthetic neurotensin analogs capable of crossing the blood-brain 
barrier, such as NT69L (Tyler et al., 1999) and PD149163 (Wustrow et al., 1995). 
There is an emerging line of research examining the role of neurotensin in anxiety and 
the potential of neurotensin receptor agonists to treat anxiety disorders. In post traumatic stress 
disorder, Maes et al. (1999) reported high levels of prolyl endopeptidase, a degradation enzyme 
of neurotensin, in blood plasma, suggesting lower levels of neurotensin in these patients (Maes et 
al., 1999).  Corresponding with these findings, Ruiz et al. (1992) found lower levels of 
neurotensin in blood plasma of those with either an anxiety disorder or depression, which were 
raised upon recovery. Both NTS1 and NTS2 receptors are also found in the amygdala, including 
basolateral amygdala and central nucleus (Boudin et al., 1996; Lantos et al., 1996; Sarret et al., 
2003).  
An early suggestion that neurotensin might exhibit anxiolytic-like effects was 
demonstrated by Elliot et al. (1986) who found that intracranial neurotensin administration led 
rats to spend more time in the center versus the perimeter of an open field. Shilling & Feifel 
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Table 1) attenuated fear-potentiated startle in rats. The peptide ß-lactotensin, which has a 
preferential affinity as an agonist for NTS2 receptors over NTS1 receptors (Yamauchi et al., 
2003), has also been shown to weaken fear conditioning and attenuate the effects of restraint 
stress measured during a hole-board test (Yamauchi et al., 2006), increase the time spent in open 
elevated plus maze arms, and time spent in the center of an open field (Hou et al., 2011).  
A model becoming increasingly used to screen anxiolytic drugs is the footshock 
conditioned 22-kHz ultrasonic vocalization (USV) model in rats (Molewijk et al., 1995; Sánchez, 
2003; Simola, 2015). Calls at this frequency are produced when rats are confronted with natural 
predators (Brudzynski, 2015) and increase as the distance to a predator decreases (Litvin, 
Blanchard, & Blanchard, 2007). Audio playback of rat 22-kHz calls to non-conditioned rats 
produces increased c-fos activity in brain regions associated with fear conditioning, such as the 
amygdala and periaqueductal grey area. These calls also correlate with defensive behaviors such 
as conditioned freezing and staying in the closed arms of an elevated plus maze (Borta et al., 
2006). In a previous study from this laboratory, Prus et al. (2014) demonstrated that PD149163 
significantly reduced footshock conditioned 22-kHz USVs in rats, which was a result typical of 
anxiolytic drugs such as the 5-HT1A partial agonist buspirone (Molewijk et al., 1995; Prus et al., 
2014) and some benzodiazepines (Molewijk et al., 1995). Chou et al. (2015) measured 22-kHz 
USVs in rats performing a conditioned avoidance response task, and in these animals, PD149163 
also reduced 22-kHz USVs.  
  The aim of the current study was to add to past findings on the effects of neurotensin 
ligands on anxiety by testing the CNS effects of PD149163, neurotensin and the NTS2 receptor 
agonist Boc-[Ψ11,12]NT(8-13) (JMV-431) (Dubuc et al., 1999; Richard et al., 2001; Table 1) in 
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5 
reduce USVs in this model, but an assessment of neurotensin has not been evaluated. Studies 
have yet to be conducted using a selective NTS2 receptor agonist in this model. In order to 
closely compare the effects of these selective ligands with neurotensin, which does not cross the 
blood-brain barrier, all compounds were microinjected into the lateral ventricle. 
2. Results 
 Animals that did not emit at least 80 vocalizations during a test after conditioning were 
eliminated prior to surgery and data were removed for rats with incorrect cannula placements. 
Based on this, data were analyzed from 19 rats [PD149169 (N=7), JMV-431 (N=7) and NT 
(N=5)].  There was not a statistically significant difference (p > 0.05) between the first and 
second vehicle assessments on the number of USV calls for either neurotensin [t(4)=0.95, p > 
0.05], PD149163 [t(6)=0.12, p > 0.05], or JMV-431[t(6)=0.02, p > 0.05]; moreover, the vehicle 
data for neurotensin, PD149163 or JMV-431 did not differ significantly between these groups, 
F(2, 16) = 1.13, p > 0.05. Neurotensin (0.1, 1.0, and 10.0μg) significantly reduced the number of 
USV calls, F(3,12) = 6.69, p < 0.05, and post hoc testing found significantly fewer calls for only 
10 μg of neurotensin compared to vehicle (figure 1). PD149163 (0.1, 1.0, & 10.0 ng) also 
significantly reduced USV calls, F(3,18) = 17.33, p < 0.001, which occurred as a reduction in 
calls following administration of 10 ng of PD149163 compared to vehicle (figure 2, top panel). 
JMV-431 (0.1 and 1.0μg) significantly reduced the number of calls F(2,12) = 19.08, p < 0.001, 
following administration of 1.0μg compared to vehicle (figure 2, bottom panel). 
 There was not a significant difference between the USV call durations of the first and 
second vehicle tests for any of the drugs evaluated (data not shown), nor did USV call durations 
for vehicle differ between the treatment groups. None of the compounds tested produced 






































































In the present study, intracerebroventricular administration of the neuropeptide 
neurotensin, the selective NTS1 receptor agonist PD149163, and the selective NTS2 receptor 
agonist JMV-431 produced a significant reduction in footshock conditioned 22-kHz USV calls in 
rats, an effect considered predictive of anxiolytic efficacy (e.g., Molewijk et al., 1995; Simola, 
2015).  These reductions were shown for the “long” type of 22-kHz USVs (approx. 1s), which 
are the length of calls emitted from rats presented with threatening stimuli (Simola, 2015). As 
addressed in the introduction, several past studies suggest an anxiolytic profile for neurotensin 
and a role for anxiolytic effects via activation of NTS1 or NTS2 receptors. In particular, a past 
study in this laboratory found that systemic administration of PD149163 significantly reduced 
22-kHz USVs using procedures similar to those in the present study (Prus et al., 2014). In the 
present study, PD149163 was 1,000 fold more potent than neurotensin (0.01 vs 10.0 ug, 
respectively) and 100 fold more potent than JMV-431 (1.0 ug) in reducing the number of 22-kHz 
calls emitted. Graded dose response curves were not shown for these compounds, likely due to 
using 10-fold differences between each dose. 
Brain neurotensin systems may have specific relationships with mechanisms mediating 
conditioned 22-kHz USV production, but it seems more likely that neurotensin and neurotensin 
receptor agonists reduce 22-kHz USVs by acting to reduce anxiety.  Numerous pharmacological 
studies link cholinergic activity and cholinergic muscarinic receptor activation to the production 
of 22-kHz USVs (for review see Brudzynski, 2015); neurotensin’s interactions with cholinergic 
systems (Szigethy et al., 1988) enhances the activity of cholinergic neurons (Alonso et al., 1994; 
Gully et al., 1997) leading to acetylcholine efflux (e.g., Gully et al., 1997; Kitabgi and Freychet, 
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alone, neurotensin might be predicted to enhance 22-kHZ USVs, which is the opposite of what is 
found.  
Likely, the ability of neurotensin and its agonists to reduce the emission of 22-kHz USVs 
occurs through processing and conditioning of fear responses, as has been demonstrated by 
neurotensin, NTS1 receptor agonists and NTS2 receptor agonists in past studies noted earlier. 
Dense neurotensin-containing fibers terminate in the central nucleus of the amygdala (CeA) 
(Jennes et al., 1982), and the basolateral amygdala (BLA) and CeA contain high levels of NTS1 
and NTS2 receptors (Boudin et al., 1996; Lantos et al., 1996; Sarret et al., 2003). Neurotensin 
receptors may alter glutamatergic neurotransmission in the amygdala, which may alter fear 
conditioning processes. Neurotensin has been shown to facilitate NMDA-elicited increases in 
glutamate (Ferraro et al., 2011) and NTS1 receptor activation may disinhibit BLA pyramidal 
neurons, thereby promoting long-term potentiation (Kroner et al., 2005). Beyond glutamate 
interactions, there is evidence that neurotensin receptors interact with neurotransmitters with 
terminals in the amygdala, including dopamine (Asan, 1998) and serotonin (Boudin et al., 1996; 
Jolas and Aghajanian, 1996; Sarret et al., 2003). 
 The present study provided further evidence that neurotensin receptor mechanisms appear 
involved in fear conditioning processes and that agonists for neurotensin receptors may be 
pursued as novel anxiolytic drugs. Neurotensin, like the NTS1 receptor agonist PD148163 in a 
previous study (Prus et al., 2014), exhibited an attenuation on footshock-conditioned USVs, 
suggesting that neurotensin plays a natural role in reducing anxiety. The findings with JMV-431 
also support anxiolytic effects ocurring through NTS2 receptor activation. These receptors, in 
particular, are worth pursuing as a novel pharmacologic strategy for treating anxiety as NTS1, but 
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(Dal Farra et al., 2001). JMV-431 does not readily cross the blood-brain barrier (unpublished 
findings), and therefore, there is a need for highly selective and brain penetrant NTS2 receptor 
agonists in order to assess the clinical utility of such compounds in animal models. 
4. Experimental Procedure 
4.1 Subjects 
 Thirty male Wistar rats (Charles River Laboratories, Portage, MI) were used in this study 
and housed in a temperature and humidity controlled vivarium set on a 12 hr light/dark cycle. 
Rats were 10-12 weeks old when experiments began. All procedures were approved by the 
Institutional Animal Care and Use Committee at Northern Michigan University and followed the 
Guide for the Care and Use of Laboratory Animals (National Research Council Committee for 
the Update of the Guide for the Care and Use of Laboratory Animals et al., 2011). 
4.2 Pharmacological compounds      
 The test compounds consisted of neurotensin (0.1, 1.0, & 10.0μg doses, AnaSpec, 
Fremont, CA, USA), PD149163 HCl (0.1, 1.0, & 10ng doses) and JMV-431 (0.1 & 1.0µg) (both 
generously provided by the NIMH Drug Repository, Bethesda, MD, USA). All compounds were 
dissolved in a phosphate buffering solution (Sigma-Aldrich, St. Louis, MO) with 1.2 mM CaCl 
added. The salt form of PD149163 was used. 
An Equithesin solution was used for as an injectable (i.p.) surgical anesthesia for the 
majority of the animals; later in the study, during experiments to test JMV-431, an isoflurane 
vaporizer became available for gas surgical anesthesia and was used instead. An injection (s.c.) 
of Penicillin G (Butler Schein Animal Health, Dublin, OH, USA) was given after an animal was 
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given twice a day as an analgesic for two days following surgery. Animals were given one week 
to recover before testing began. 
4.3 Apparatus and materials 
  Each test compound for this study was injected into the right lateral ventricle via a  
26 ga. guide cannulae (C315G-SPC; PlasticsOne, Roanoke, VA, USA) that was surgically 
installed using a rodent stereotaxic device (Stoelting Co., Wood Dale, IL, USA). A matching 33 
ga. dummy cannula (C315DC-SPC, PlasticsOne) was implanted into the guide immediately 
following surgery and the dummy cannula was replaced by a 33 ga. injection cannula (C315I-
SPC, PlasticsOne) for drug injection prior to a test session. A syringe pump (MD-1001, 
Bioanalytical Systems, Inc., Lafayette, IN, USA) injected a drug solution through an injection 
cannula at a rate of 2μL per minute.  
 Conditioning and testing sessions were conducted using an ultrasonic vocalization 
chamber equipped with a shock grid floor and USV detector (Med Associates, St. Albans, VT, 
USA). Two key lights positioned at the front of the chamber were used for illumination during 
experimental sessions.  All experimental events and data recording were conducted using MED 
PC version 4 software (Med Associates). 
4.4 Surgical and behavioral procedures 
 Prior to the cannula implantation surgery, rats were first footshock conditioned to the 
USV chamber and then pre-tested to determine if conditioning produced 22-kHz USVs. The pre-
training/testing procedures were modified from those described previously by this laboratory 
(Prus et al., 2014). Conditioning was conducted during two consecutive daily sessions. During 
these sessions, each rat was exposed to 6 floor grid shocks (0.8 mA, 8s duration) pseudo-
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seconds were randomly selected after a shock was presented 60 seconds after the beginning of 
the training session. A pre-test session was conducted on the following day.  
The pre-test session consisted of two trials. The first trial was 2 min long and one shock 
(0.8 mA, 8 s duration) was given approximately halfway through the trial.  The rat was removed 
from the chamber at the end of this trial and then returned to the chamber 30 min later for the 
second trial.  The second trial was 10 min long.  During this trial 22-kHz USVs were recorded 
and no shocks were administered. Rats that failed to emit at least 80 USVs were excluded from 
the study prior to surgery. This training requirement was used in Molewijk et al. (1995).  
A single guide cannula was installed in the right lateral ventricle at anterior/posterior = -
1.0 mm, medial/lateral = +2.0 mm relative to bregma and at a depth of 2 mm from the skull 
surface according to stereotaxic coordinates (Paxinos and Watson, 2005) and fixed using 
cranioplastic cement.  The injection cannula, when implanted prior to a test session, extended 2 
mm beyond the tip of the guide cannula to reach the lateral ventricle. Rats were given one week 
to recover from surgery before testing sessions were conducted.   
The testing procedure was conducted over the course of consecutive daily sessions. The 
first session consisted of a conditioned session as described above. The remaining sessions were 
test sessions as described earlier, except that the dummy cannula was replaced with an injection 
cannula immediately after the 2 min trial.  After implanting the injection cannula, 2µL of drug or 
vehicle solution (i.e., the phosphate buffering solution) was perfused through the cannula for one 
minute.  The syringe pump was then deactivated and remained connected to the injection cannula 
for an additional minute before disconnecting it. The dummy cannula was replaced after the 
injection cannula was removed. The 10 min test trial was conducted 30 min after the injection. 
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day and drug doses were then escalated by 10 fold for each subsequent daily test session. The 
final test day for each compound consisted of a second administration of phosphate buffering 
solution to assess if changes in the number of USVs occurred to baseline responding after drug 
testing.  Daily doses were increased instead of counterbalanced due to evidence of PD149163 
producing behavioral tolerance in the USV preparation (Prus, Hillhouse, & LaCrosse, 2014). 
Following testing, the probe placements were verified using histology and data were excluded 
for incorrect placements.  
Data Analysis   
The number and duration (s) of 22-kHz calls were reported as means (+/- standard error 
of the mean [SEM]). As noted earlier, a vehicle test was conducted before drug testing and after 
drug testing; a paired samples t test was subsequently conducted to determine if these before and 
after vehicle data differed significantly. Means for each animal of the before and after tests were 
calculated and used as the vehicle condition for subsequent analyses. A one-way repeated 
measures analysis of variance was used to assess differences across doses and vehicle for each 
compound. Dunnett’s post hoc tests were used to compare doses to vehicle, when appropriate, at 
the p < 0.05 level. Statistical analyses were conducted using Graph Pad Prism 6 software 
(GraphPad Software, Inc., La Jolla, CA). 
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Figure 1. The effects of the neuropeptide neurotensin on USV calls in male Wistar rats 
(N=5). USV calls (means +/- SEM) refer to 22-kHz vocalizations. The abscissa refers to amounts 
of the compounds administered icv. * P < 0.05 compared to 0.0 Pg (i.e., vehicle).  
 
Figure 2. The effects of the NTS1 receptor agonist PD149163 (N=7) (top) and the NTS2 
receptor agonist JMV-431 (N=7) (bottom) on USV calls. ***P < 0.001 compared to 0.0 Pg or 
0.0 ng (i.e., vehicle). See figure 1 for further details. 
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Table 1. Binding affinities for NTS1 and NTS2 receptors 
Compound NTS1 NTS2 Reference 
Neurotensin 0.2 nM (Kd) 4nM (Kd) Vincent et al. 1999 
PD149163 159 nM (Ki) No affinity Petrie et al. 2004 
JMV-431 3315 nM (Ki) 38 nM (Ki) Dubuc et al. 1999 
 
Table 1
Table 2.  USV call durations 
Compound Dose Mean (SEM) USV Call 
Duration (s) 
Neurotensin Vehicle 
0.1 μg 
1.0 μg 
10.0 μg 
1.10 (0.12) 
1.08 (0.14) 
0.88 (0.15) 
1.08 (0.05) 
PD149163 Vehicle 
0.1 ng 
1.0 ng 
10.0 ng 
1.14 (0.08) 
1.15 (0.12) 
1.09 (0.09) 
1.02 (0.05) 
JMV-431 Vehicle 
1.0 μg 
10.0 μg 
1.12 (0.10) 
1.09 (0.09) 
0.95 (0.05) 
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